Included in the formulation
АТХ:L.04.A.A.33 Vedolizumab
Pharmacodynamics:Selectively inhibits the integrated receptors, blocking their interaction with T-lymphocytes, mast cells, basophils and monocytes. Prevents the development of an inflammatory reaction in the mucosa of the gastrointestinal tract.
Pharmacokinetics:After intravenous administration, the maximum concentration in the blood plasma is reached after 5-10 minutes.
The half-life is 25 days. Elimination by the kidneys.
Indications:It is used for the treatment of ulcerative colitis and Crohn's disease.
XI.K50-K52.K51.9 Ulcerative colitis, unspecified
XI.K50-K52.K50.9 Crohn's disease, unspecified
Contraindications:Acute infectious diseases, the presence of severe allergic reactions in the anamnesis, age under 18 years, individual intolerance.
Carefully:Presence of chronic inflammatory infections, tuberculosis.
Pregnancy and lactation:Recommendations for FDA - Category B. It is used during pregnancy and lactation.
Dosing and Administration:Intravenous drip, 300 mg in a 0.9% solution of sodium chloride. Treatment schedule is individual.
The highest daily dose: 300 mg.
The highest single dose: 300 mg.
Side effects:Respiratory system: nasopharyngitis.
Hematopoietic system: neutropenia.
Digestive system: diarrhea.
Dermatological reactions: hives.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:
In the treatment and within 6 months after its end It is not recommended to vaccinate with live vaccines.